表紙
市場調查報告書
商品編碼
1025477

Dipeptidyl Peptidase4(DPP-4)抑制劑的全球市場預測(2020年∼2026年)

Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market 2020-2026

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球Dipeptidyl Peptidase4(DPP-4)抑制劑的市場規模,在預測期間(2020年∼2026年)中預計以3.5%緩慢的年複合成長率擴大。促進這個市場成長的主要原因,是在全球糖尿病,尤其是第二型糖尿病的罹患率上升。Dipeptidyl Peptidase4(DPP-4)抑制劑,幫助在患者體內的胰島素分泌,調節體內的糖等級。這樣的要素,促進預測期間的市場成長。可是,作為醫藥品攝取了Dipeptidyl Peptidase4(DPP-4)抑制劑上產生的許多副作用,成為妨礙市場成長的要素。

本報告提供全球Dipeptidyl Peptidase4(DPP-4)抑制劑市場相關調查分析,市場概要,市場決策要素,市場區隔,競爭情形,各地區分析,主要企業等相關的系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和最新的市場趨勢

第3章 競爭情形

  • 競爭的儀表板
  • 主要策略分析
  • 主要企業分析
    • Merck & Co.
    • Novartis AG
    • Eli Lily &Co.
    • Boehringer Ingelheim International GmbH

第4章 市場決策要素

  • 成長要素
  • 阻礙因素
  • 市場機會

第5章 市場區隔

  • 各藥物類型的全球DPP-4抑制劑市場
    • Sitagliptin
    • Vildagliptin
    • Saxagliptin
    • Linagliptin
    • Gemigliptin
    • Anagliptin
    • Teneligliptin
    • 其他

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • ASEAN
    • 韓國
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Eli Lily & Co.
  • GlaxoSmithKline Plc
  • Kowa Co. Ltd.
  • LG Life Sciences Ltd.
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Phenomix Corp.
  • Sanofi SA
  • Sanwa Kagaku Kenkyusho Co. Ltd.
  • SatRx LLC
  • Takeda Pharmaceutical Co.
目錄
Product Code: OMR2023916

Full-title:Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size, Share & Trends Analysis Report by Drug Type (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others) Forecast, 2020-2026.

The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is projected to grow at a modest CAGR of 3.5% during the forecast period (2020-2026). The key aspect that drives the growth of the market includes the rising incidences of diabetes particularly type 2 among the people across the globe. The prevalence of diabetes in 2019 across the globe was more than 463 million and is projected to increase over the forecast period as per the International Diabetes Federation (IDF)'s projections. The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body. Hence, such factors are likely to enhance the growth of the market over the forecast period. However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors in form of drugs challenge the growth of the market.

The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type. Based on the drug type, the market is segmented as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others. Amongst these drug types of the global dipeptidyl peptidase 4 (DPP-4) inhibitors, the Sitagliptin and Saxagliptin are projected to hold the most lucrative share in the market. Geographically, the global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North American region is anticipated to grow considerably over the forecast period. 

Further, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, Phenomix Corp., and Takeda Pharmaceutical Co. among others are some of the prominent players functioning in the global dipeptidyl peptidase 4 (DPP-4) inhibitors market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market. 

Research Methodology

The market study of the global dipeptidyl peptidase 4 (DPP-4) inhibitors market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Research and Analysis by Drug Type

The Report Covers

  • Comprehensive research methodology of the global dipeptidyl peptidase 4 (DPP-4) inhibitors market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Dipeptidyl peptidase 4 (DPP-4) inhibitors market.
  • Insights about market determinants which are stimulating the global dipeptidyl peptidase 4 (DPP-4) inhibitors market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Industry
  • Recovery Scenario of Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Competitive Dashboard
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Merck & Co.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Novartis AG
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Eli Lily &Co.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Boehringer Ingelheim International GmbH
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market by Drug Type
    • 5.1.1. Sitagliptin
    • 5.1.2. Vildagliptin
    • 5.1.3. Saxagliptin
    • 5.1.4. Linagliptin
    • 5.1.5. Gemigliptin
    • 5.1.6. Anagliptin
    • 5.1.7. Teneligliptin
    • 5.1.8. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. ASEAN
    • 6.3.5. South Korea
    • 6.3.6. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AstraZeneca Plc
  • 7.2. Boehringer Ingelheim International GmbH
  • 7.3. Bristol Myers Squibb Co.
  • 7.4. Eli Lily & Co.
  • 7.5. GlaxoSmithKline Plc
  • 7.6. Kowa Co. Ltd.
  • 7.7. LG Life Sciences Ltd.
  • 7.8. Merck & Co.
  • 7.9. Novartis AG
  • 7.10. Pfizer Inc.
  • 7.11. Phenomix Corp.
  • 7.12. Sanofi SA
  • 7.13. Sanwa Kagaku Kenkyusho Co. Ltd.
  • 7.14. SatRx LLC
  • 7.15. Takeda Pharmaceutical Co.

LIST OF TABLES

  • 1. GLOBAL DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL SITAGLIPTINMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL VILDAGLIPTINMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL SAXAGLIPTIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL LINAGLIPTIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL GEMIGLIPTIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL ANAGLIPTINMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL TENELIGLIPTIN MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL OTHERDRUG TYPES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
  • 13. EUROPEAN DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. EUROPEAN DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
  • 15. ASIA-PACIFIC DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 16. ASIA-PACIFIC DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
  • 17. REST OF THE WORLD DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SHARE BY DRUG TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 3. US DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 4. CANADA DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. UK DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. FRANCE DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. GERMANY DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. ITALY DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. SPAIN DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ROE DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. INDIA DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. CHINA DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. JAPAN DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. ASEAN DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. SOUTH KOREA DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
  • 17. REST OF THE WORLD DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)